An echinocandin antifungal drug, that inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls.
Intravenous agent .
Trade name Mycamine
99.8% protein bound, with a 11-17 hour half life.
Excretion with 40% in feces, and < 15% in urine.
iIndicated for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, abscesses and esophageal candidiasis.
Approved for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
A concentration-dependent inhibitor of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, which is an essential polysaccharide comprising one-third of the majority of Candida spp. cell walls
results in decreased glucan production and leads to osmotic instability and thus cellular lysis.
For the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, the dosage of micafungin is 100 mg once daily.
For the treatment of esophageal candidiasis, the dosage is 150 mg once daily.
For prophylaxis of Candida infections in HSCT recipients, the dosage is 50 mg once daily.
The metabolism of micafungin occurs hepatically as the drug molecule is a substrate of CYP3A4, which is a liver enzyme.